Amgen at neutral by Merrill

Amgen Inc. was given a neutral rating by Merrill Lynch analyst Eric Ende. The company filed its response to Roche's motion to dismiss its infringement suit, while Roche has filed its NDA for CERA. Further arguments regarding a case or controversy meeting and safe harbor issues are scheduled for May 10. Shares of the Thousand Oaks, Calif., biotechnology company were up $0.89, or 1.34%, at $67.37 on volume of 11,152,252 shares versus the three-month running average of 11,405,900 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.